Provided by Tiger Fintech (Singapore) Pte. Ltd.

Unum Therapeutics

2.35
+0.0000
Volume:- -
Turnover:- -
Market Cap:99.80M
PE:-2.73
High:2.35
Open:2.35
Low:2.35
Close:2.35
Loading ...

Company Profile

Company Name:
Unum Therapeutics
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Unum Therapeutics Inc., a biopharmaceutical company, focuses on developing a pipeline of novel therapies to treat cancer patients. The company's novel proprietary technology, known as Bolt-On Chimeric Receptor (BOXR), is designed to improve the functionality of engineered T cells by discovering and incorporating a ‘bolt-on' transgene into a patients' engineered T cells to overcome resistance of the solid tumor microenvironment to T cell attack. Its advanced program, PLX9486, is a selective KIT D816V inhibitor that is being developed to treat patients with systemic mastocytosis and gastrointestinal stromal tumors. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.